ANIK Q1 2023 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$213M

Q1 2023 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$38M+3.4% YoY

Gross Profit

$23M60.2% margin

Operating Income

-$13M-33.1% margin

Net Income

-$10M-27.3% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

-4.3%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$5M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$339M

Total Liabilities

$61M

Stockholders' Equity

$278M

Cash & Equivalents

$80M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38M	$37M	+3.4%
Gross Profit	$23M	$22M	+4.8%
Operating Income	-$13M	-$4M	-253.2%
Net Income	-$10M	-$3M	-252.9%

Revenue Segments

OA Pain Management

$23M60%

Joint Preservation and Restoration

$13M35%

Non-Orthopedic

$2M5%

Geographic Segments

UNITED STATES

$27M83%

Europe

$6M17%